Literature DB >> 30115702

CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells-Response.

Fernando P Canale1, María C Ramello1, Nicolás Núñez2, Sabrina N Bossio1, Eliane Piaggio2,3, Adriana Gruppi1, Eva V Acosta Rodríguez1, Carolina L Montes4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30115702     DOI： 10.1158/0008-5472.CAN-18-0950

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  9 in total

1.  Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes.

Authors:  David M Woods; Andressa S Laino; Aidan Winters; Jason Alexandre; Daniel Freeman; Vinay Rao; Santi S Adavani; Jeffery S Weber; Pratip K Chattopadhyay
Journal:  JCI Insight       Date:  2020-06-04

2.  Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.

Authors:  Junyun Lai; Sherly Mardiana; Imran G House; Kevin Sek; Melissa A Henderson; Lauren Giuffrida; Amanda X Y Chen; Kirsten L Todd; Emma V Petley; Jack D Chan; Emma M Carrington; Andrew M Lew; Benjamin J Solomon; Joseph A Trapani; Katherine Kedzierska; Maximilien Evrard; Stephin J Vervoort; Jason Waithman; Phillip K Darcy; Paul A Beavis
Journal:  Nat Immunol       Date:  2020-05-18       Impact factor: 25.606

3.  Deciphering the Plasmodium falciparum malaria-specific CD4+ T-cell response: ex vivo detection of high frequencies of PD-1+TIGIT+ EXP1-specific CD4+ T cells using a novel HLA-DR11-restricted MHC class II tetramer.

Authors:  Sophia Schulte; Janna Heide; Christin Ackermann; Sven Peine; Michael Ramharter; Maria Sophia Mackroth; Robin Woost; Thomas Jacobs; Julian Schulze Zur Wiesch
Journal:  Clin Exp Immunol       Date:  2022-04-04       Impact factor: 4.330

4.  Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19.

Authors:  Laura A Vella; Josephine R Giles; Amy E Baxter; Derek A Oldridge; Caroline Diorio; Leticia Kuri-Cervantes; Cécile Alanio; M Betina Pampena; Jennifer E Wu; Zeyu Chen; Yinghui Jane Huang; Elizabeth M Anderson; Sigrid Gouma; Kevin O McNerney; Julie Chase; Chakkapong Burudpakdee; Jessica H Lee; Sokratis A Apostolidis; Alexander C Huang; Divij Mathew; Oliva Kuthuru; Eileen C Goodwin; Madison E Weirick; Marcus J Bolton; Claudia P Arevalo; Andre Ramos; C J Jasen; Peyton E Conrey; Samir Sayed; Heather M Giannini; Kurt D'Andrea; Nuala J Meyer; Edward M Behrens; Hamid Bassiri; Scott E Hensley; Sarah E Henrickson; David T Teachey; Michael R Betts; E John Wherry
Journal:  Sci Immunol       Date:  2021-03-02

5.  Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies.

Authors:  Shamin Li; Yannick Simoni; Summer Zhuang; Austin Gabel; Shaokang Ma; Jonathan Chee; Laura Islas; Anthony Cessna; Jenette Creaney; Robert K Bradley; Alec Redwood; Bruce W Robinson; Evan W Newell
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-27       Impact factor: 12.779

6.  Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies.

Authors:  Katia Beider; Orit Itzhaki; Jacob Schachter; Ania Hava Grushchenko-Polaq; Valeria Voevoda-Dimenshtein; Evgenia Rosenberg; Olga Ostrovsky; Olivia Devillers; Ronnie Shapira Frommer; Li-At Zeltzer; Amos Toren; Elad Jacoby; Avichai Shimoni; Abraham Avigdor; Arnon Nagler; Michal J Besser
Journal:  Cells       Date:  2022-03-28       Impact factor: 6.600

7.  B cells from Patients with Rheumatoid Arthritis Show Conserved CD39-Mediated Regulatory Function and increased CD39 Expression After Positive Response to Therapy.

Authors:  E R Zacca; M C Amezcua Vesely; P V Ferrero; C D V Acosta; N E Ponce; S N Bossio; E Mussano; L Onetti; I Cadile; E V Acosta Rodríguez; C L Montes; A Gruppi
Journal:  J Mol Biol       Date:  2020-10-22       Impact factor: 6.151

8.  MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC.

Authors:  Jiae Koh; Youjin Kim; Kyoung Young Lee; Joon Young Hur; Mi Soon Kim; Boram Kim; Hee Jin Cho; Yeong Chan Lee; Yeon Hee Bae; Bo Mi Ku; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  Eur J Immunol       Date:  2020-07-09       Impact factor: 5.532

9.  Enhanced CXCR4 Expression of Human CD8Low T Lymphocytes Is Driven by S1P4.

Authors:  Tobias Burkard; Caroline Dreis; Martina Herrero San Juan; Meik Huhn; Andreas Weigert; Josef M Pfeilschifter; Heinfried H Radeke
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.